Want to see KRBPQ full AI Analyst Report?

Kiromic Biopharma (KRBPQ) Price & Analysis

20 Followers

KRBPQ Stock Chart & Stats

$0.04

Market closed

$0.04

Day’s Range― - ―

52-Week Range$0.03 - $1.80

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.09K

Market Cap

$157.00

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-4.13

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,570,919

10 Day Avg. Volume3,734

30 Day Avg. Volume3,091

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovative Technology PlatformsKiromic Biopharma's focus on proprietary technology platforms in immuno-oncology positions it to potentially revolutionize cancer treatment, offering long-term competitive advantages in the biotechnology sector.

Focus On Immuno-OncologyKiromic's specialization in immuno-oncology taps into a growing sector with significant demand for innovative cancer therapies, potentially driving future revenue and market leadership.

Strategic AlliancesPartnerships with larger companies can enhance Kiromic's financial stability and market penetration, crucial for sustaining operations and achieving long-term growth in the competitive biotech industry.

Bears Say

Increasing LossesRising losses reflect high R&D expenses without offsetting revenue, challenging Kiromic's financial sustainability and necessitating strategic pivots to achieve profitability.

Lack Of RevenueThe absence of revenue is a critical concern, as it limits Kiromic's ability to sustain operations and invest in R&D, potentially hindering long-term growth and competitiveness.

Negative EquityNegative equity suggests financial instability, posing risks to Kiromic's long-term viability and ability to fund its operations without significant restructuring or additional capital.

Kiromic Biopharma News

Kiromic Biopharma’s Innovative Cancer Treatment Study: A Potential Game-Changer

Kiromic Biopharma, Inc. (($KRBPQ)) announced an update on their ongoing clinical study. Kiromic Biopharma, Inc. is conducting a...

9M ago

KRBPQ

KRBPQ FAQ

What was Kiromic Biopharma’s price range in the past 12 months?

Kiromic Biopharma lowest stock price was $0.03 and its highest was $1.80 in the past 12 months.

What is Kiromic Biopharma’s market cap?

Kiromic Biopharma’s market cap is $157.00.

When is Kiromic Biopharma’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kiromic Biopharma’s earnings last quarter?

Currently, no data Available

Is Kiromic Biopharma overvalued?

According to Wall Street analysts Kiromic Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kiromic Biopharma pay dividends?

Kiromic Biopharma does not currently pay dividends.

What is Kiromic Biopharma’s EPS estimate?

Kiromic Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kiromic Biopharma have?

Kiromic Biopharma has 1,570,919 shares outstanding.

What happened to Kiromic Biopharma’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kiromic Biopharma?

Currently, no hedge funds are holding shares in KRBPQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kiromic Biopharma

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.